Future Proofing & Incentives Among Industry Priorities In EU Pharma Law Shake UP
Overhaul of the pharmaceutical legislation in the EU is an opportunity to learn from COVID-19, says European industry body.
You may also be interested in...
The incentives system, access to medicines, future proofing for novel products and antimicrobial resistance are just some of the topics included in a new consultation.
The “chronic disease paradigm” presents a real challenge for companies marketing advanced therapies.
Value assessments of COVID-19 monoclonal antibodies should inform pricing decisions, says cross country coalition.